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Laboratory-based surveillance,  one of the pillars of 
monitoring infectious disease trends, relies on data 
produced in clinical and/or public health laboratories. 
Currently, diagnostic laboratories  worldwide submit 
strains or samples to a relatively small number of ref-
erence laboratories for characterisation and typing. 
However, with the introduction of molecular diag-
nostic methods and sequencing in most of the larger 
diagnostic and university hospital centres in high-
income countries, the distinction between diagnostic 
and reference/public health laboratory functions has 
become less clear-cut. Given these developments, 
new ways of networking and data sharing are needed. 
Assuming that clinical and public health laboratories 
may be able to use the same data for their own pur-
poses when sequence-based testing and typing are 
used, we explored ways to develop a collaborative 
approach and a jointly owned database (TYPENED) 
in the Netherlands.  The rationale was that sequence 
data – whether produced to support clinical care or for 
surveillance –can be aggregated to meet both needs. 
Here we describe the development of the TYPENED 
approach and supporting infrastructure, and the 
implementation of a pilot laboratory network sharing 
enterovirus sequences and metadata. 
Introduction
Laboratory-based surveillance is one of the pillars of 
monitoring infectious disease trends, which is based 
on data from clinical and/or public health laboratories. 
This type of surveillance is performed for a range of 
food- and waterborne, sexually transmitted and blood-
borne diseases, respiratory pathogens or zoonotic 
pathogens and provides important input for national 
and international disease surveillance, to evaluate 
the impact of control and prevention measures, and to 
detect clusters or relevant changes in pathogen pres-
ence and/or behaviour [1-3]. 
One problem in the use of laboratory-based surveil-
lance systems is that they require information that 
typically is collected at the clinical level and therefore 
is not focused on surveillance.  For certain priority dis-
eases, such as polio and measles, this issue has been 
solved by making the identification of a case notifi-
able, in which case the laboratory or the clinician or 
both are required to provide structured information for 
surveillance to a national or international dedicated 
organisation. For non-notifiable diseases, however, 
the need for standardisation to ensure data compara-
bility between laboratories may be at odds with the 
rapid developments in clinical microbiology labora-
tories [4-6]. In the Netherlands, currently, diagnostic 
laboratories routinely submit strains or samples to 
reference laboratories for characterisation and typing. 
However, with the introduction of molecular diagnos-
tic methods in most of the larger diagnostic centres, 
the distinction between diagnostic and reference labo-
ratory functions has become less clear-cut. Multiplex 
real-time PCR and sequence-based detection and typ-
ing techniques may be used for clinical diagnosis, to 
guide treatment (by, for example, resistance profiling, 
strain characterisation and typing), for hospital infec-
tion control and quality management (for cluster detec-
tion). The methods and analytical tools employed for 
these functions potentially overlap with what is needed 
for national and international or cross-border surveil-
lance. The expected introduction of next generation 
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sequencing techniques in routine diagnostic settings 
within the next five years is likely to further lift the 
borders between the previously separated activities 
across disciplines and domains [7].
While international surveillance networks rely on ref-
erence laboratories, and each pathogen or pathogen 
group has its own network and system, often with 
centralised data collection, the latest developments 
are a challenge for these networks. As more and more 
clinical laboratories perform molecular testing meth-
ods, the reference laboratories become dependent on 
data submission by these laboratories, often with lit-
tle perceived benefit for the submitting laboratories, 
considering the extra effort required.  We anticipate 
increasing resistance from clinical laboratories to data 
requests for surveillance purposes because of these 
competing priorities. 
Given these developments, we consider that new ways 
of networking of data and data sharing are needed. 
Assuming that clinical and public health laborato-
ries may be able to use the same data for their own 
purposes when sequence-based testing and typing 
are used, we explored ways to develop a collabora-
tive approach and a jointly owned database in the 
Netherlands. Here we describe the development of the 
approach and supporting infrastructure, and the imple-
mentation of a pilot laboratory network sharing entero-
virus sequences and metadata.  
Methods
Partnership
An initiative set up by a group of opinion leaders in 
microbiology in the Netherlands to draw attention to 
the changing needs of and demands placed on clini-
cal laboratories and the need for standardisation to 
ensure data comparability and sharing between labo-
ratories. Within this initiative, called TYPENED (TYPeer 
netwerk NEDerland [Typing network Netherlands]), two 
pilots were started in 2009: one for bacterial typing 
and one for viruses.  In the VIRO-TYPENED pilot, five 
universities and one regional laboratory collaborated 
with the National Institute of Public Health and the 
Environment (RIVM) to develop a new model of col-
laboration for virology based on sequence informa-
tion gathered in the routine diagnostic setting.  These 
laboratories have all been long-term suppliers of sur-
veillance information, by sending to RIVM isolates or 
clinical specimens as well as clinical information for 
a number of viruses such as influenza A virus, noro-
virus, enterovirus, rotavirus and hepatitis A, B and E 
viruses. All participating laboratories have molecular 
diagnostic testing facilities and perform sequencing as 
part of their routine diagnostics for specific clinical or 
research questions on one or more of these pathogens 
(Figure 1, first ring of clinical laboratories surrounding 
the national reference laboratory). Using a centralised 
database structure at the national reference labora-
tory level, expert clinical laboratories can still have 
Figure 1
Conceptual model for TYPENED, showing laboratories 
with different capacities
1
4
3
2
National reference laboratory: national focal point
Expert clinical laboratory: reference role
Cinical laboratory: diagnostic and typing service
Clinical laboratory: diagnostic service
TYPENED: TYPeer netwerk NEDerland [Typing network 
Netherlands].
1, 2, 3 and 4 represent a specialist laboratory, dealing with, 
for example, samples from food, water, the environment and 
animals.
The laboratory capacities range from routine diagnostic functions, 
diagnostics and typing functions, expert-level services (includes 
research), and national reference-level functions.  
The dark circle indicates the hub from which the molecular 
platform infrastructure is provided (see Figure 2). Based on 
areas of expertise (indicated by numbers), coordination of the 
network activities may be delegated from the national focal 
point to a local laboratory, while maintaining the common 
infrastructure. 
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their own network activities with collaborating local 
diagnostic laboratories (Figure 1, showing the group 
of  diagnostic laboratories that refer molecular typing 
data to the laboratories indicated by ‘3’ or ‘4’). 
Selection of pilot pathogens
An inventory was made of the currently used typing 
methods in the six clinical laboratories and the pub-
lic health laboratory participating in VIRO-TYPENED 
using a structured online questionnaire. Participants 
were asked to list those viruses for which they had 
typing methods operational in their laboratories and 
the purpose of those typing applications, and to indi-
cate for which viruses they would like to see joint 
action, and at which level. The options provided were: 
(i) the exchange of protocols, control reagents and 
quality-control panels; (ii) a centralised reference data 
collection; (iii) a common database; and (iv) no col-
laboration considered necessary.  The purpose of this 
inventory was to identify areas for which there was 
a common need, as well as areas where joint action 
was not considered advantageous. A second part of 
the inventory asked about methods used and the fre-
quency of typing in each laboratory. 
Molecular platform database
In order to achieve efficiency and continuity, a generic 
database infrastructure for sharing of molecular typing 
data and metadata was developed at RIVM between 
2008 and 2011. The platform consists of a web data-
base and a set of analysis modules. The database can 
be configured for a specific pathogen, at the request 
Figure 2
Conceptual model for data sharing platform for TYPENED collaboration between the national public health institute and 
clinical laboratories in a laboraty network
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Laboratories submit data to a joint database. The data comprise sequence data and background data on the sample and the patient (case). All 
sequences are typed automatically. A set of online analysis modules is available for all participants to mine the data.  Data can be analysed 
for trends or clusters in time and place. Sequence data can be analysed for similarity and phylogenetic clustering. Elevations are identified 
through an automatic cluster detection algorithm based on both sequence information and epidemiological parameters. 
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of a laboratory network, which also appoints a coor-
dinator or curator. User types can be defined, coupled 
with tailored access rights. The two central entities 
are sample and sequence. A minimal dataset can 
be defined by the network, based on the questions 
addressed, coupled with a feasibility assessment. This 
dataset minimally comprises time and place, but can 
be complemented with additional epidemiological or 
clinical metadata specific to the targeted organism. 
Besides online data entry forms, the platform provides 
a bulk upload option using Microsoft Excel and FASTA 
formats.
All sequences submitted to the database are auto-
matically typed in a standardised way using a web-
based typing tool [8]. Sequence data can be analysed 
by carrying out built-in similarity searches using the 
BLAST algorithm, and by generating pie charts, inci-
dence plots, geographical maps and phylogenetic 
trees (neighbour-joining clustering method, with a 
two-parameter Kimura nucleotide-substitution model, 
with or without bootstrapping). The added value of a 
database like this – compared with the database of 
GenBank [9], in which laboratories all over the world 
share their sequences – is threefold. Firstly, the data 
are more comparable because of the agreed typing 
region and the standardised typing results and sec-
ondly, the data are shared before laboratories have 
decided to make them publicly available, for example, 
through GenBank. The third important advantage is the 
linked, standardised set of epidemiological and clinical 
data with each sequence, which allows in-depth analy-
sis. A description of the components and functions of 
the molecular platform is shown in Figure 2. 
Pilot study: enteroviruses
On the basis of the inventory results, the seven labo-
ratories agreed to start the pilot with enterovirus 
as a test pathogen. A minimum dataset was agreed, 
including age and sex of patient, type of sample from 
which the virus was detected, whether the patient was 
hospitalised, travel history (by country visited), clini-
cal symptoms in broad categories (skin, neurological, 
respiratory, enteric). For each patient, at least one 
sequence of the major capsid protein VP1 gene has to 
be provided of the agreed genomic region (nucleotides 
2,604–2,909 NC_001612, CVA16). In addition, samples 
that could not be typed as an enterovirus but were 
typed as poliovirus-like, were sent to the enterovirus 
section of the Center for Infectious Disease Control 
at RIVM, as part of the enterovirus surveillance pro-
gramme in place, to document the absence of wild-type 
poliovirus circulation.  
Data sharing and confidentiality agreement
Participants worked with a confidentiality agreement, 
consenting to the use of the data to provide surveil-
lance overviews and alerts and to the right to publish 
the data, with proper acknowledgement, in case of 
public health emergencies.  All participants can access 
and download the data, but they cannot be used with-
out the consent of the data provider.
Enterovirus diagnostics and sequencing
Each laboratory used a laboratory-developed test, 
adapted from the protocol described by Nix et al. 
[10] (2006) for the detection of enteroviruses. One 
laboratory used an additional protocol described by 
McWilliam Leitch et al. [11] for cerebrospinal fluid sam-
ples. All laboratories participated in an external profi-
ciency testing programme organised through Quality 
Control for Molecular Diagnostics (QCMD), Glasgow, 
United Kingdom, an International Organization of 
Standardization (ISO) 17043-accredited organisation. 
Amplification of the 5’ non-coding region of entero-
virus was performed at the individual participating 
laboratory. 
Genotype assignment using a standardised sequence-
based typing tool
 Upon entering of sequences into the database, an 
automated algorithm was run to assign the genotype. 
This tool has been validated against most currently 
known picornaviruses and has been shown to correlate 
highly with the serotype assignment [8]. 
Results
Questionnaire information
In addition to enterovirus, the seven participating labo-
ratories indicated that they performed systematic gen-
otyping for influenza virus (n=7), hepatitis B virus (n=6) 
and hepatitis C virus (n=5), primarily related to moni-
toring of treatment. Some laboratories also typed pare-
choviruses (n=5), rhinoviruses (n=3), hepatitis E virus 
(n=3), norovirus (n=2), hepatitis A virus (n=2), cyto-
megalovirus (n=2), herpes simplex virus (HSV) (n=2), 
adenovirus (n=2), human immunodeficiency virus (HIV) 
(n=3), as well as hepatitis B virus and hepatitis C virus 
for specific research or clinical study-related questions. 
A need for a more structured collaboration between the 
laboratories, possibly including the operation of a joint 
reference database, was indicated by the majority of 
respondents regarding influenza virus, parechovirus, 
rhinovirus and hepatitis B virus. For the less commonly 
used typing approaches, a need for collaboration was 
expressed for hepatitis viruses A, C and E.  Given the 
consensus that a type of collaborative network would 
meet a need, a pilot TYPENED database was set up for 
enteroviruses. 
Pilot enterovirus database
As of 1 May 2012, a total of 651 human enterovirus (HEV) 
sequences were submitted to the TYPENED database, 
representing all enterovirus-positive clinical samples 
that were successfully sequenced at six of the collabo-
rating laboratories from 1 January 2010 to 31 December 
2011.  Most of the sequences belonged to HEV-A 
(n=168; 25.8%) and B (n=466; 71.6%), whereas only a 
few belonged to HEV-C (n=6; 0.9%) and D (n=6; 0.9%). 
Following automatic typing of the sequences submitted 
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to the TYPENED database, it appeared that some of the 
viruses that were enterovirus positive in the molecular 
diagnostic assay appeared to be a rhinovirus A (n=5; 
0.8%), most probably due to the cross-reactivity of the 
primers used for detection. In addition, three poliovi-
rus sequences were identified within the HEV-C set: all 
three isolates were obtained from children from the for-
mer Netherlands Antilles (Curaçao and Sint Maarten), 
where oral polio vaccines were used. 
The laboratories that submitted the sequences received 
samples from laboratories all over the Netherlands. 
Although the numbers per serotype were not always 
very large, some clusters of serotypes over time could 
be observed (detailed data not shown). For example, 
of the 48 CV-A9 sequences submitted, 43 were found 
in samples collected from May to August 2010 with a 
clear peak (n=38) in June and July.  In addition,  five of 
the six EV-D68 sequences were found in samples col-
lected from August to November 2010; 46 of the 65 E-7 
sequences were found in samples collected from May 
to August 2011 and 51 of the 69 E-25 sequences were 
found in samples collected from August to December 
2011.
Discussion
We have described a data-sharing concept that com-
bines the capacities of clinical and public health labo-
ratories in the Netherlands in a database to which all 
laboratories have equal and full access. After initial 
discussions to align expectations and develop a code 
of conduct, all laboratories were able to share a first 
set of historical data within two months. One of the 
triggers for the development of this concept was the 
concern that current enterovirus surveillance which 
is based on cell culture isolation is no longer the pre-
ferred method for enterovirus detection at hospital 
level and information obtained through other typing 
methods would not be captured centrally [12].  
We managed to get consensus on the typing protocol 
and a data sharing agreement between the central 
public health laboratory (RIVM), large university labo-
ratories and some large general hospitals that are geo-
graphically dispersed, thus potentially enabling broad 
coverage of surveillance of viruses of common interest. 
Within the enterovirus pilot, all sequences generated 
in two years by six of the seven collaborating laborato-
ries were shared. 
One pitfall of a consensus typing method may be that 
some viruses will be missed if they are not detected in 
the particular molecular test. This is of concern, given 
that the previously common practice of viral culture, 
which could serve as a safety net, is diminishing very 
rapidly. Most laboratories maintain these culture facili-
ties only to grow control material for molecular assays. 
Since RNA viruses diverge rapidly, there is a need to 
get updated full-length sequences, not only for epide-
miological reasons but also to keep diagnostic assays 
based on molecular testing up to date. At present, the 
availability of whole genome sequences is limited, but 
with next generation sequencing techniques rapidly 
coming within reach of academic and even clinical lab-
oratories, this situation will change quickly.  
The same system is currently being set up for a num-
ber of other viruses  for which collaboration was valued 
according to the questionnaire – with parechovirus, 
norovirus and hepatitis E virus on the priority list [13-
15]. Sequence-based characterisation is becoming 
more common within the larger diagnostic centres: the 
availability of sequence-based information will assist 
both the clinicians and diagnostic laboratories as well 
as the public health laboratories. 
The concept of TYPENED in the Netherlands has been 
shown to be an effective means of close collaboration 
and the participating laboratories are willing to extend 
this collaboration to other targets. Furthermore, by 
using sequencing technologies, a more in-depth analy-
sis of circulating strains can be carried out, as individ-
ual sequences can be analysed, instead of serotypes. 
Sequences have a much higher discriminatory power, 
as most sequences within one serotype will be differ-
ent from each other, thus facilitating, for example, the 
tracing of transmission patterns. Sequence techniques 
are particularly valuable for viruses that are difficult to 
grow. In an economic climate with shrinking budgets, it 
may prove difficult for facilities to perform sequencing 
for diagnostic and epidemiological purposes, although 
it is expected that large centres will continue to per-
form routine sequencing. The TYPENED model seeks to 
maximise the use of data generated both in clinical and 
public health laboratories, for clinical care and for sur-
veillance purposes. The harmonisation of typing proto-
cols and sharing of data with a more extensive group 
of laboratories, or even cross-border centres, will be a 
next step.
6 www.eurosurveillance.org
References
1. Bean NH, Martin SM. Implementing a network for electronic 
surveillance reporting from public health reference 
laboratories: an international perspective. Emerg Infect Dis. 
2001;7(5):773-9. 
2. Emori TG, Gaynes RP. An overview of nosocomial infections, 
including the role of the microbiology laboratory. Clin 
Microbiol Rev. 1993;6(4):428-42. 
3. Workman MR, Wall PG, Tearle P, O’Mahony M, Brunton WA. 
Active surveillance of health and safety in microbiology 
laboratories. Commun Dis Rep CDR Rev. 1995;5(4):R54-6. 
4. Deyde VM, Sampath R, Gubareva LV. RT-PCR/electrospray 
ionization mass spectrometry approach in detection and 
characterization of influenza viruses. Expert Rev Mol Diagn. 
2011;11(1):41-52. 
5. Endimiani A, Hujer KM, Hujer AM, Kurz S, Jacobs MR, Perlin 
DS, et al. Are we ready for novel detection methods to treat 
respiratory pathogens in hospital-acquired pneumonia? Clin 
Infect Dis. 2011;52 Suppl 4:S373-83. 
6. Fournier-Wirth C, Coste J. Nanotechnologies for pathogen 
detection: Future alternatives? Biologicals. 2010;38(1):9-13. 
Epub 2010 Jan 15. 
7. Aarestrup FM, Brown EW, Detter C, Gerner-Smidt P, Gilmour 
MW, Harmsen D, et al. Integrating genome-based informatics 
to modernize global disease monitoring, information sharing, 
and response. Emerg Infect Dis. 2012;18(11):e1. 
8. Kroneman A, Vennema H, Deforche K, v d Avoort H, Peñaranda 
S, Oberste MS, et al. An automated genotyping tool for 
enteroviruses and noroviruses. J Clin Virol. 2011(2):121-5. 
9. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, 
Lipman DJ, Ostell J, et al. GenBank. Nucleic Acids Res. 
2013;41(D1):D36-42. 
10. Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR 
amplification of VP1 sequences for direct identification of all 
enterovirus serotypes from original clinical specimens. J Clin 
Microbiol. 2006;44(8):2698-704. 
11. McWilliam Leitch EC, Harvala H, Robertson I, Ubillos I, 
Templeton K, Simmonds P. et al. (2009). Direct identification 
of human enterovirus serotypes in cerebrospinal fluid by 
amplification and sequencing of the VP1 region. J Clin Virol. 
44(2):119-24. 
12. Manzara S, Muscillo M, La Rosa G, Marianelli C, Cattani P, 
Fadda G. Molecular identification and typing of enteroviruses 
isolated from clinical specimens. J Clin Microbiol. 
2002;40(12):4554-60. 
13. Wolthers KC, Benschop KS, Schinkel J, Molenkamp R, 
Bergevoet RM, Spijkerman IJ, et al. Human parechoviruses as 
an important viral cause of sepsislike illness and meningitis in 
young children. Clin Infect Dis. 2008;47(3):358-63. 
14. Nelson KE, Kmush B, Labrique AB. The epidemiology of 
hepatitis E virus infections in developed countries and among 
immunocompromised patients. Expert Rev Anti Infect Ther. 
2011;9(12):1133-48. 
15. Verhoef L, Williams KP, Kroneman A, Sobral B, van Pelt W, 
Koopmans M; et al. Selection of a phylogenetically informative 
region of the norovirus genome for outbreak linkage. Virus 
Genes. 2012;44(1):8-18.
